Order Article Reprints

Wind SS, Jansen MAA, Rijsbergen M, van Esdonk MJ, Ziagkos D, Cheng WC, Niemeyer-van der Kolk T, Korsten J, Gruszka A, Schmitz-Rohmer D, et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers. 2022; 14(6):1510. https://doi.org/10.3390/cancers14061510

Wind, Selinde S., Manon A. A. Jansen, Melanie Rijsbergen, Michiel J. van Esdonk, Dimitrios Ziagkos, Wing C. Cheng, Tessa Niemeyer-van der Kolk, John Korsten, Agnieszka Gruszka, Debora Schmitz-Rohmer, and et al. 2022. "Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial" Cancers 14, no. 6: 1510. https://doi.org/10.3390/cancers14061510

Wind, S. S., Jansen, M. A. A., Rijsbergen, M., van Esdonk, M. J., Ziagkos, D., Cheng, W. C., Niemeyer-van der Kolk, T., Korsten, J., Gruszka, A., Schmitz-Rohmer, D., Bonnel, D., Legouffe, R., Barré, F., Bekkenk, M. W., de Haas, E. R. M., Quint, K. D., Schnidar, H., Rolli, M., Streefkerk, H. J., ... Rissmann, R. (2022). Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers, 14(6), 1510. https://doi.org/10.3390/cancers14061510